ERBB2 and acute myeloid leukemia: This is consistent with the contemporary and generally preferred treatment approach for HER2+ disease, as an anthracycline containing chemotherapy regimen added to anti‐HER2 therapy does not improve treatment efficacy but does increase cardiotoxicity and risk of treatment associated acute myeloid leukemia compared with an anthracycline free regimen.10, 17